Skip to main content
Signal8
Launch Terminal

GALECTIN THERAPEUTICS INC (GALT)

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Galectin Therapeutics Inc. logo

Galectin Therapeutics Inc.

NASDAQ:GALTHealthcare
-5.68%$3.32
AH$3.32+0.00%vs close
Mkt Cap$334.82M
Float66.88M
O/S100.85M
Vol
$ Vol
RVOL
Inst Own15.5%
SI13.7%
Earnings
Dilution
Galectin Therapeutics Inc. logoNASDAQ:GALT$3.32-5.68%
Phase Distribution
10 lead-sponsored trials·0 active·6 completed
Phase 13
Phase 26
Phase 2/31
(3 more as collaborator)
Status Overview
Completed6
Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2/3
    Terminated

    Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

    belapectin, Placebo

    Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis +1

    Enrollment
    357
    Start
    Jun 2020
    Primary Completion
    Mar 2025
    Completion
    Apr 2025
    NCT04365868
  • Phase 2
    Terminated

    GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

    GM-CT-01 plus 5-Fluorouracil

    Colorectal Cancer

    Enrollment
    20
    Start
    May 2005
    Primary Completion
    Jun 2007
    Completion
    Feb 2008
    NCT00110721
  • Phase 2
    Withdrawn

    Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

    GM-CT-01, 5-Fluorouracil

    Cancer of the Bile Duct, Gallbladder Cancer

    Enrollment
    0
    Start
    Sep 2006
    Primary Completion
    Jun 2009
    Completion
    Jun 2009
    NCT00386516
  • Phase 2
    Withdrawn

    A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

    GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab

    Colorectal Cancer

    Enrollment
    0
    Start
    Oct 2006
    Primary Completion
    Jun 2009
    Completion
    Jun 2009
    NCT00388700
  • Phase 2
    Completed

    An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

    GR-MD-02

    Psoriasis

    Enrollment
    5
    Start
    Sep 2015
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT02407041
  • Phase 2
    Completed

    Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

    GR-MD-02, Placebo

    Nonalcoholic Steatohepatitis

    Enrollment
    30
    Start
    Sep 2015
    Primary Completion
    Sep 2016
    Completion
    Sep 2016
    NCT02421094
  • Phase 2
    Completed

    Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

    GR-MD-02, Placebo

    Hypertension, Portal

    Enrollment
    162
    Start
    Jun 2015
    Primary Completion
    Oct 2017
    Completion
    Oct 2017
    NCT02462967
  • Phase 1
    Completed

    Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

    GM-CT-01, 5-fluorouracil

    Colorectal Cancer, Lung Cancer +3

    Enrollment
    40
    Start
    Feb 2003
    Primary Completion
    Apr 2005
    Completion
    Sep 2006
    NCT00054977
  • Phase 1
    Completed

    Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

    GR-MD-02, Placebo

    Non-Alcoholic Steatohepatitis (NASH)

    Enrollment
    31
    Start
    Jul 2013
    Primary Completion
    Feb 2015
    Completion
    Feb 2015
    NCT01899859
  • Phase 1
    Completed

    GT-032 Belapectin Hepatic Impairment

    belapectin

    Hepatic Impairment

    Enrollment
    38
    Start
    Jun 2020
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT04332432
Search ClinicalTrials.gov for “Galectin Therapeutics”